Abstract: Human epidermal growth factor receptor-2 (HER-2)-positive breast cancer is highly malignant and has poor prognosis. The emergence of anti-HER-2 targeted drugs has altered clinical outcomes of patients with HER-2-positive breast cancer. However, the efficacy of these drugs is affected by treatment at different disease stages. The treatment strategy at an early disease stage will affect treatment selection at a late disease stage. In the past, the drug regimen was determined according to different treatment lines, which could not reflect the stratified therapy concept of targeted drugs. Currently, a stratified treatment model for anti-HER-2 therapy has been established based on previous medication of patients and evidence-based medicine combined with guidelines and clinical experience. This study aimed to review stratified strategies for HER-2-positive breast cancer at different stages.